Alectinib versus crizotinib in <scp>ALK</scp> ‐positive advanced non‐small cell lung cancer and comparison of next‐generation <scp>TKIs</scp> after crizotinib failure: Real‐world evidence-Reference-Cited by-同舟云学术

Alectinib versus crizotinib in ALK ‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

Published:2022-05-26 Issue:23 Volume:11 Page:4491-4500
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Wang Yurong¹^ORCID,Shen Shujing²,Hu Peizhu³,Geng Di¹,Zheng Ruipan²,Li Xingya¹^ORCID

Affiliation:

1. Department of Medical Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan Province People's Republic of China

2. Department of Radiotherapy The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan Province People's Republic of China

3. Department of Pathology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan Province People's Republic of China

Funder

Zhengzhou University

Innovationsfonden

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4834

Reference20 articles.

1. New and emerging targeted treatments in advanced non-small-cell lung cancer

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

4. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

5. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of non-canonical ALK fusion on the efficacy of targeted therapy in non-small cell lung cancer;Chinese Medical Journal;2023-11-29

2. Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach;Cancer Chemotherapy and Pharmacology;2023-10-14

3. Ceritinib/crizotinib;Reactions Weekly;2023-07-01

4. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study;Targeted Oncology;2023-06-21

5. Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study;Journal of Thoracic Disease;2023-05